Navigation Links
Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
Date:8/1/2012

NATICK, Mass., Aug. 1, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced publication of preclinical models utilizing their proprietary SINE compounds in AML. SINEs specifically and irreversibly inhibit the nuclear transporter exportin 1 (XPO1), more commonly called CRM1 (chromosome region maintenance 1). CRM1 is the exclusive mediator of the nuclear export of p53, p73, pRb, FOXO, p21, p27, BRACA1, and other tumor suppressor proteins, along with the endogenous inhibitor of Nuclear Factor kB (NF-kB) known as IkB. Cancer cells use nuclear export of these key anti-tumor proteins to functionally inactivate them. Blockade of CRM1 with SINE leads to accumulation and activation of tumor suppressor and chemotherapy resistance proteins in the nucleus, leading to selective tumor cell apoptosis while sparing normal cells.

(Logo: http://photos.prnewswire.com/prnh/20120508/NE02031LOGO )

Romero Garzon, MD, PhD, and colleagues at the Ohio State University published a plenary paper in the journal Blood entitled, "Pre-clinical activity of a novel CRM1 inhibitor in acute myeloid leukemia" (PubMed ID: 22677130). The authors showed that Karyopharm's SINE compounds induced apoptosis at nanomolar levels in AML cell lines and in AML blasts from patients. SINEs reduced the levels of the AML oncoprotein FLT3, and when given orally to mice, prolonged their survival with good tolerability.

In the second paper, Tom Look, MD, and colleagues at the Dana Farber Cancer Institute in Boston published a paper in the journal Leukemia entitled "Anti-leukemic activity of nuclear export inhibitors that spare normal hematopoietic cells" (PubMed ID: 22847027). This paper describes the discovery of the SINE compounds based on the X-ray crystal structure of CRM1 using proprietary in silico screening methods developed by Karyopharm's fo
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
3. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
4. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
5. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
6. Juventas Therapeutics Raises $22.2 Million Series B Financing
7. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
8. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
9. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
10. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
11. United Therapeutics Announces Additional $100 Million Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... NEW DELHI, India, July 17 Following ... the stock market, Daiichi Sankyo,Company, Limited (TSE: ... Ranbaxy/500359) ("Ranbaxy") reiterate that the agreement,between Daiichi ... largest,controlling shareholders of Ranbaxy, is binding and ...
... the efforts of two kinds of bacteria to produce hydrogen ... for the other. According to an article in the August ... added bonus: leftover enzymes can be used to scavenge precious ... that convert hydrogen into energy. , Hydrogen has three times ...
... July 16 US Oncology Holdings, Inc. and ... second quarter,financial results on Thursday, August 7, 2008., ... been scheduled at 11:00,a.m., EDT, for the company,s ... this call, representatives of US Oncology,s management,team will ...
Cached Biology Technology:Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2Fuel from food waste: bacteria provide power 2
(Date:7/9/2014)... some shark species may be able to cope with the ... temperatures. , The Arctic today is best known for its ... that. Roughly 53 to 38 million years ago during what ... similar to a huge temperate forest with brackish water, home ... hippo-like creatures, crocodiles and giant tortoises. Much of what is ...
(Date:7/9/2014)... and fever but often can be defeated with antibiotics ... to beat. Now, scientists have built a new weapon against ... in the journal ACS Applied Materials & Interfaces , ... more of them than medicine alone. , David Leong, Jianping ... in wait, undetectable in the human body or in places ...
(Date:7/9/2014)... The re-examination of a sparrow-sized fossil from China challenges ... theropod dinosaurs that gained the ability to fly. The ... thought, but much rather the remains of a tiny ... Czerkas of the Dinosaur Museum in Blanding, Utah, and ... study appears in Springer,s Journal of Ornithology . ...
Breaking Biology News(10 mins):Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
... WEST LAFAYETTE, Ind. - A Purdue University scientist has found ... unfavorable conditions, a finding he believes could one day be ... environments. David Salt, a professor of horticulture, noticed several ... thaliana that could tolerate higher levels of sodium had come ...
... 31, 2011A compact, self-contained, automated system for surveillance and ... deadly infectious diseases is a step closer to reality, ... the University of California Los Angeles School of Public ... from LANL and the UCLA School of Public Health ...
... and Torosaurus have long been considered the ... the giants, family tree further back in time, when a ... more well-known descendants, making it the earliest known member of ... after the Greek myth of the Titans, rivaled ...
Cached Biology News:Plants can adapt genetically to survive harsh environments 2LANL to certify automated influenza surveillance system 2LANL to certify automated influenza surveillance system 3Newly discovered dinosaur likely father of Triceratops 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: